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ABSTRACT
CONTEXT AND OBJECTIVE: The role of immune response and proinflammatory cytokines in the pathogenesis of chronic pain has been of growing 
interest. In order to evaluate whether there is any association between disc herniation and elevated cytokine levels, we measured cytokine levels in 
patients with chronic low back pain and in healthy subjects.
DESIGN AND SETTING: Analytical cross-sectional study at the Pain Clinic of Universidade Federal da Bahia (UFBA).
METHODS: Cytokine levels were measured using the enzyme-linked immunosorbent assay (ELISA) technique on 23 patients with low back pain (G1) 
and on 10 healthy subjects (G2). 
RESULTS: The levels of tumor necrosis factor-alpha [TNF-alpha] (G1 = 5.6 ± 2.3 pg/ml; G2 = 1.6 ± 0.5 pg/ml; P = 0.01) and interleukin-6 
[IL-6] (G1 = 4.1 ± 3.0 pg/ml; G2 = 0.9 ± 0.4 pg/ml; P = 0.01) were higher in G1. There were no statistically significant differences in relation to 
interleukin-1 [IL-1] (G1 = 0.5 ± 0.3 pg/ml; G2 = 0.5 ± 0.1 pg/ml; P = 1) or soluble tumor necrosis factor receptor [sTNF-R] (G1 = 572 pg/ml ± 36; 
G2 = 581 ± 50 pg/ml; P = 0.87). 
CONCLUSION: The patients with chronic low back pain due to disc herniation presented higher levels of TNF-alpha and IL-6, but not of IL-1 or 
sTNF-R. 
RESUMO
CONTEXTO E OBJETIVO: A função da resposta imunológica e das citocinas pró-inflamatórias na patogênese da dor crônica tem tido interesse 
crescente. Para avaliar se há correlação entre hérnia de disco e aumento de citocinas, foi medida a concentração de citocinas em pacientes com 
lombalgia crônica e em indivíduos sadios.
TIPO DE ESTUDO E LOCAL: Estudo transversal analítico realizado na Clínica de Dor da Universidade Federal da Bahia (UFBA).
MÉTODO: As concentrações de citocinas foram medidas pela técnica de ELISA (enzyme linked immunosorbent assay) em 23 pacientes com 
lombalgia (G1) e 10 sadios (G2). 
RESULTADOS: As concentrações de fator-alfa de necrose tumoral [TNF-alpha] (G1 = 5.6 ± 2.3 pg/ml; G2 = 1.6 ± 0.5 pg/ml; P = 0,01) e 
interleucina-6 [IL-6] (G1 = 4.1 ± 3.0 pg/ml; G2 = 0.9 ± 0.4 pg/ml; P = 0,01) foram maiores no G1. Não houve diferença estatisticamente 
significante para interleucina-1 [IL-1] (G1 = 0.5 ± 0.3 pg/ml; G2 = 0.5 ± 0.1 pg/ml; P = 1) e receptor solúvel do factor de necrose tumoral [sTNF-R] 
(G1 = 572 pg/ml ± 36; G2 = 581 ± 50 pg/ml; P = 0,87). 
CONCLUSÃO: Os pacientes com lombalgia crônica por hérnia de disco apresentam concentrações maiores de TNF-alpha e IL-6, mas não de IL-1 
ou sTNF-R.
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Low back pain is extremely prevalent. It impairs individuals’ qual-
ity of life and work capability, and thus has important social and eco-
nomic implications.1 Approximately 60% to 80% of the United States 
population will experience back pain at some point during their lives 
and, at any given time, 55% suffer from low back pain associated with 
radicular syndromes. Moreover, about 1% of the United States popu-
lation is chronically disabled because of back problems, and another 
1% is temporarily disabled.2-4 Among a variety of etiologies for low 
back pain, herniated disc disease has been postulated as an important 
cause. It has been estimated that herniated disc disease could be pres-
ent in 4% to 12% of patients with low back pain and could affect 5% 
of adults, according to population-based surveys.5-9 Sciatica symptoms 
are very persistent in nature over time, and up to one third of all such 
patients undergo lumbar surgery.10 
Mechanical compression of peripheral nerve roots results in tis-
sue damage, thereby causing inflammation with a direct effect on 
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neurological function. Such injuries are potentially responsible for 
spontaneous discharges and increased amplitude of the electrical sig-
naling response of the lumbar nerve roots, as demonstrated in animal 
models.11 
It has been suggested that these injuries may modulate neuroim-
mune cascades, particularly the upregulation of cytokines in the dam-
aged area, which may induce the expression of numerous algesic media-
tors that ultimately lead to pain.12,13 The extent of cytokine production 
is complex and may be influenced by the degree of nuclear exposure at 
the herniation site. Previous studies have examined whether circulating 
proinflammatory cytokine levels become elevated in syndromes associ-
ated with chronic pain, but mixed results have been reported.14-17 The 
cytokines that could present abnormal levels in blood and cerebrospi-
nal fluid include interleukin-8 (IL-8), interleukin-1 (IL-1), tumor ne-
crosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and soluble TNF 
receptor (sTNF-R).18 One challenge in interpreting the cytokine levels 
reported in many papers has been the limited information on healthy 
norms and reference values.19,20
OBJECTIVE
The aim of this study was to evaluate the prevalence of elevated se-
rum cytokine levels in patients with chronic pain due to herniated disc 
disease, compared with healthy subjects.  
METHODS
Study population
After this analytical cross-sectional study had gained approval 
from the institutional ethics committee, patients were included fol-
lowing the signature of a written informed consent statement. In this 
manner, 23 consecutive patients with at least three months of back 
pain due to herniated disc disease were selected from the Pain Clinic 
of Universidade Federal da Bahia (UFBA). They were compared with 
10 healthy subjects from the hospital community (with ages ranging 
from 20 to 65 years), without any previous history of back pain, who 
were used as controls. 
The diagnosis was confirmed by means of magnetic resonance imag-
ing (MRI) or computed tomography (CT) imaging of the spine, for all 
the patients. In addition, for patients to be included in the study, their 
pain severity had to be ≥ 5 points on a numerical rating scale (NRS), 
which ranged from zero (no pain) to 10 (worst imaginable pain). 
The exclusion criteria were defined as the presence of one or more of 
the following: psychiatric disorders, systemic or inflammatory diseases, 
histories of allergy, presence of motor deficits, histories of blood dyscra-
sia, pregnancy, active infection, tumors, use of analgesic drugs during 
the preceding week, or inability to come to the hospital for evaluation. 
All patients underwent standard history-taking and physical ex-
amination. Neurological findings (sensory and motor deficits and re-
flex dysfunction) and the straight leg-raising test were also evaluated by 
means of clinical examination. All the data were registered to facilitate 
statistical analysis. 
In this study, the sample size calculation was based on different stud-
ies in the literature (between 10 and 30 patients) and on the fact that 
normal individuals do not present circulating proinflammatory serum 
cytokines. A difference in serum cytokine levels of at least 4.0 pg/ml be-
tween the healthy volunteers and the patients with low back pain was 
considered clinically significant. On the basis of other studies, we esti-
mated the within-group standard deviation (SD) for serum cytokines as 
3.5. For a power of 0.95 and alpha = 0.05, the sample size was about 
20 patients.
Laboratory determinations
Five milliliters of venous blood was drawn in the morning from the 
subjects and immediately centrifuged. The serum was stored at –20 °C. 
The serum levels of the proinflammatory cytokines IL-1 beta, TNF-al-
pha, IL-6 and sTNF-R were measured using a commercially available 
quantitative sandwich enzyme immunoassay technique (R&D Systems, 
Minneapolis, Minnesota, United States). Briefly, a microplate was coated 
with a monoclonal antibody that was specific for the cytokines, and stan-
dards and samples were pipetted into the wells. After washing, an enzyme-
linked polyclonal antibody that was specific for the cytokines was added. 
The reaction was revealed by addition of the substrate solution. 
Data analysis
The variables did not present a normal distribution, and therefore 
nonparametric tests were used. The cytokine levels were compared be-
tween the study and control groups using the Mann-Whitney test. The 
Spearman coefficient was used to determine the relationship between 
cytokines and continuous variables. The chi-square or Fisher exact test 
was used when necessary, to test differences between proportions. The 
Statistical Package for the Social Sciences (SPSS) statistical software (ver-
sion 10.0, SPSS Inc., Chicago, Illinois, United States) was used for data 
analysis, and statistical significance was determined as P values < 0.05.
RESULTS
Twenty-three patients were enrolled in the study: 52% were men and 
74% were black. The mean age was 42.8 ± 7.0 years (median 42.0); the 
mean weight was 67.7 ± 9.0 kg (median 64.8); and the mean height was 
165.1 ± 9.1 cm (median 167.0) (Table 1). The pain duration among the 
herniated disc patients was 81 ± 99 months (median 34.5) and the pain 
intensity as measured using the numerical rating scale was 9.0 ± 1.7 (me-
dian 10). The location of the herniated intervertebral disc was at the L4-
L5 levels in 61% of the patients and at the L5-S1 levels in 39%. Pain 
was continuous in 78% of the subjects, with a daily frequency in 87%. 
The neurological findings were: a positive straight-leg-raise test (35%); 
hyporeflexia (17%); hypoesthesia (52%); and reduced muscle strength 
(4%) Table 2. As shown in Table 3, serum levels of TNF-alpha and IL-6 
were statistically higher in G1 (P < 0.05). There were no differences in 
IL-1 beta or sTNF-R levels between the groups (P > 0.05), according to 
the Mann-Whitney test. The distribution of TNF-alpha and IL-6 levels in 
these two groups is depicted in Figure 1. The correlation coefficients be-
tween serum levels of TNF-alpha or IL-6 and pain intensity were, respec-
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Figure 1. Distribution of tumor necrosis factor-alpha (TNF-α) and 
interleukin-6 (IL-6) in patients with herniated disc and controls. 
Table 1. Patients’ characteristics
Gender Age ( years) Weight (kg) Height (cm)
G1 (n = 23) 12 (M); 11 (F) 42.8 ± 7.0 67.7 ± 9.0 165.1 ± 9.1
G2 (n = 10) 6 (M); 4 (F) 39.5 ± 4.5 65.3  ± 6.8 165.3 ± 6.7 
P 0.7220* 0.1893† 0.4680‡ 0.9502‡
G1 = herniated disc patients; G2 = healthy control subjects; P = statistical significance ≥ 0.05; M = male;  
F = female; *Fisher exact test; †Mann-Whitney test; ‡Student’s t test
Table 2. Neurological findings in the group of patients with herniated disc 
(G1; n = 23)
Positive straight-leg raise test 8 (35%)
Hyporeflexia 6 (17%)
Hypoesthesia 12 (52%)
Reduced muscle strength 5 (4%)
(pg/ml) G1 (n = 23) G2 (n = 10) P
IL-1 beta 0.5 ± 0.3 0.5 ± 0.1 1
IL-6 4.1 ± 3.0 0.9 ± 0.4 0.01*
TNF-alpha 5.6 ± 2.3 1.6 ± 0.5 0.01*
sTNF-R 572 ± 36 581 ± 50 0.87
IL-1 beta = interleukin-1 beta; IL-6 = interleukin-6; TNF-alpha = tumor necrosis factor-alpha; sTNF-R = soluble 
tumor necrosis factor receptor; *P ≤ 0.05; n = number of patients; Mann-Whitney test.
Table 3. Serum cytokine levels in herniated disc patients (G1) and controls (G2)
tively, rs = 0.28, P = 0.18; rs = 0.32, P = 0.13; and in relation to duration of 
pain complaints were, respectively, rs = 0.06, P = 0.78; rs = 0.10, P = 0.64. 
There was also no correlation between the levels of proinflammatory cy-
tokines and clinical parameters like age, weight and height (P > 0.05).  
DISCUSSION
The present study demonstrates that individuals with herniated 
lumbar intervertebral disc disease have elevated serum levels of TNF-
alpha and IL-6, compared with healthy subjects. 
Disc herniation disease causes nerve root impingement, which 
leads to overexpression of cytokines and a complex network of bio-
chemical reactions that can modify the transcription factors involved 
in gene expression, expand the glial cells in the general vicinity and 
thus cause neuronal hyperexcitability. The increased concentrations of 
these substances in the herniated disc tissue suggests that cytokines 
potentially have the ability to cause endoneural edema and nerve fiber 
demyelination.21-23 Furthermore, cytokines excite nociceptors, which 
suggests that they may play a critical role in peripheral hyperalgesia and 
pain behavior.24,25 Nonetheless, the potential involvement of these sub-
stances in disc herniation may be related to a local process. Thus, docu-
mentation of elevated serum levels of proinflammatory cytokines is an 
important finding and indicates that these molecules may be involved 
in systemic inflammatory reactions and hyperalgesia. 
Although elevated serum IL-6 levels in individuals with an ongoing 
history of sciatic pain following discectomy have already been reported,15 
no such elevation has been found in subjects with disc herniation and 
sciatica.16 However, proinflammatory cytokines show circadian rhythms 
and variations in peripheral blood, and the differences can potentially 
be related to the following factors: 1) the time of the day at which the 
blood samples were drawn, based on a study that demonstrated that 
IL-6 concentrations peaked in the evening;15 2) IL-6 is a cytokine that 
increases in concentration in response to stressful conditions and may 
be affected by any emotional changes or symptom amplification;26 3) 
cytokines may be released in a time-ordered sequence;27 4) when an in-
terleukin binds to its functional receptor, the complex is internalized;28 
and 5) cytokines are also potent stimulators of the hypothalamic-pitu-
itary-adrenal (HPA) axis, either singly or in synergy with other classes of 
cytokines, thereby causing glucocorticoid release.29 Thus, a dysfunction-
al HPA axis response occurring in some patients may result in elevated 
serum cytokine levels. 
Nygaard et al. indicated that different types of disc herniation have 
different inflammatory properties.30 A recent study has demonstrated 
that intervertebral disc cells may produce TNF-alpha and IL-1 beta im-
mediately after the onset of disc herniation.31
Koch et al. observed that increasing serum levels of proinflamma-
tory cytokines (IL-1 beta, IL-2, IL-6, interferon-gamma [IFN-gamma] 
and TNF-alpha) correlated with increasing pain intensity in patients 
with chronic pain.17
High levels of proinflammatory cytokines have been reported in in-
flammatory and infectious diseases and can be correlated with disease 
severity.32,33 In this study, we did not find any other clinical illness that 
could explain the high levels of proinflammatory cytokines. On the other 
hand, our study population was small and, therefore, confounding fac-
tors could not be taken into account. Moreover, little is known regarding 
the impact of immune factors on pain from herniated discs. If proinflam-
matory circulating cytokines are mediators of pain and neuropathologi-
cal changes in these sensory neurons, their inhibition constitutes an alter-
native to surgical treatment. This would decrease costs and postoperative 
complications. The opportunities for pharmacological interventions tar-
geting the neuroinflammatory and neuroimmune components of various 
pathological conditions will be an exciting area of research. Thus, further 
research is needed to elucidate which of these processes are amenable to 
treatment and to determine the sensitivity and specificity of these observa-
tions for facilitating diagnoses, disease monitoring, and prognoses.34
CONCLUSION
Despite the small number of subjects included in this study, the pa-
tients with chronic low back pain and disc herniation exhibited signifi-
cantly higher levels of TNF-alpha and IL-6, but not of IL-1 or sTNF-R, 
compared with healthy subjects. 
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